





# CONFIDENTIAL UNIT EXCLUSION (CUE)


Mahtab Maghsudlu, MD, MPH Associate Professor Vice President for Research & Education High Institute in Transfusion Medicine















## METHODS TO MAXIMIZE SAFETY FROM DONATED UNITS

Self deferral Physician interview Confidential unit exclusion Donor deferral registry Laboratory testing Call back Modification of blood unit after collecting (leukocyte removal or physicochemical )procedures for pathogen inactivation





Testing

The risk of serological and NAT positive results among remunerated donors 2012?

Serological testing - positive samples: Remunerated vs. non-remunerated donors

Hepatitis B (HBsAg) Hepatitis C (anti-HCV) HIV ½ (anti-HIV ½) Syphilis (TPHA) 1.54 times higher\*
3.11 times higher\*
statistically insignificant (too small sample)
2.1 times higher\*

NAT testing (in serological negative donations) - positive samples:


Hepatitis B (HBV-RNR) Hepatitis C (HCV-DNR) HIV 1 (HIV1-DNR) 4.47-7,33 times higher\* 22.56-58.33 times higher\* statistically insignificant (too small sample)


\*- the difference is statistically significant


Sources: National Blood Centre statistics


### **CONFIDENTIAL UNIT EXCLUSION**


At the time of donation donors should be offered a procedure by which they could designate confidentially whether or not their blood should be transfused to others


















C	رد اور مطعدانو ( باطعانو آموز هو اینکل جور استن		
-	ویول افغانین های سیارین بیرک انمینی ایمل ایمل ایمل ایمل ایمل	میرونی میری میرونی میرو میرونی می میرونی می می می می می می می می می می می می می	Demographic characteristic
الية المحكمة المراجع الد المريح والمراجع المراجع والمراجع ال المراجع والمراجع ال	در بینیمه شد و مادی آلی بر مل آلا و توانیمان کاری در آمونی توریدانی میترد است. این آلای و بدار مادی میکند اید اور هر می موارید میلامی و این توانی میکند و بادی اید مادی این این این میکند و این اور ما و بادی این میکند و این این اید این این این میکند و این این این این این این و میکند و این میکند این این میکن این مادی میکندی این این این این این و میکند و این این مادی این این این این میکند و این این این این و بادی و میکند و این	این خطانها و مرافع المار الروی الا الله الله . المواند و مداخله من والی الا الله . المواند و مداخله المدانان المواند و مداخله المدانان المواند و مداخله المدانان المواند و مداخله المداخلة مداخلة ا	Counselling result Donor informed
من سالين	الدوائح فالوفاقي الماقتنات المله	این است. میان رواند او این این است. این است. این این والی ولی میان این این این این این این این ولی این این این این این این این این این این این این این این این این	consent









# CUE

In IBTO there is a Confidential Unit Exclusion (CUE) system.

to give the donor two bar code label that only a computer scanner can read

One bar cod affixed to the donation from and the other is discarded .





AFTER DONATING BLOOD RESPONSIBLE PERSON FOR SENDING BLOOD BAGS TO PREPARATION UNIT CHECK ALL CUES AND PICK OUT "NO "ANSWERS AND SEND THESE BLOOD BAGS AND PILOTS TO QC UNIT SEPARATELY.

ALL SCREENING TEST ARE DONE ON SAMPLES

**BLOOD BAG IS DISCARDED** 

DONOR IS DEFERRED TEMPORARY

DONOR IS FOLLOWED UP

DONOR IS CONSULTED FOR ELIGIBILITY TO DONATE

## TIME OF IMPLEMENTATION

In early 1983, the New York Blood Center introduced confidential unit exclusion .

The procedure was designed to allow members of groups at increased risk of AIDS to confidentially designate their donations for laboratory studies and not for transfusion.


In 1992 FDA analyzed available data on CUE sensitivity and specificity and stated that the CUE procedure was no longer mandatory ,and its use was left to discretion of each individual blood center. In other countries, such as in the <u>United Kingdom, Switzerland</u>, <u>Iran</u> and <u>Germany</u> It is still recommended.

#### **Effectiveness of CUE**

The effectiveness of could differ among blood centers due to:

- 1) various method of administer
- 2) TTI epidemiology variability
- 3) characteristics of laboratory test

1.1.1			1.2.4		OR At least one	1.00
City	Year(study)	population	CUE		TTI	CI
مازندران	1384	16781	87	%0.5	3.3	(6.97-1.61)
Tehran	1385	14320	2864	%0.9	7.2	(9.8-5.32)
شيراز	1385	75314	537	%0.7	7.2	(11.93-4.31)
Tehran	1387	353612	2072	%0.6	5.8	(7.65-4.37)
		2000	1000		10.1	(78.98-1.29)
Shiraz	1391	101245	2365	%2.3	2.2	(4.97-0.96)
قم	3-1382	12935	204	%1.6	3.8	(6.01-2.42)
بوشهر	1385-1384	39921	909	%2.3	8.5	(12.31-5.84)
Yazd	1389-1383	255932	1172	%0.5	4.8	(7.57-3.1)
اصفهان	1390-1384	436894	1824	%0.4	8.6	(11.37-6.49)
يزد	1392-1388	120841	1117	%0.9	7.3	(13.39-3.93)
کر دستان	1392-1390	73841	740	%1.0	3.9	(6.54-2.31)
كهگيلويه و بوير احمد	1393-1385	167341	1767	%1.1	5.5	(8.99-3.36)



No         351540         IIR5           Yes         2072         33           Anti-HCV         0.000         20.03         6.57-15.60         0.0958         0.000           No         251540         772         22         22         24         25 <th>ID Marker</th> <th>Number of Donations</th> <th>Number of Positive</th> <th>Pvalue</th> <th>OR.*</th> <th>95%-01</th> <th>Senaltivity</th> <th>PPV</th>	ID Marker	Number of Donations	Number of Positive	Pvalue	OR.*	95%-01	Senaltivity	PPV
No         151540         1005           Yes         2072         32           Anti-HCV         0.000         30.43         6.57-85.60         0.0958         0.0908           No         251540         277         23         -         -         -         -         -         -         0.0908         0.0958         0.0908         0.0908         -	HisAg			0.000	4.63	3.25-6.60	0.0263	0.0154
Anti-HCV         0.000         30.23         6.57-85.60         0.0958         0.0006           N0         323540         777         33         - <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
No         253540 20072         773 232           *Aldereviation: OR, add rates         20072         232           *Aldereviation: OR, add rates         *         5           Table 4. The Prevalences of HIW and HCV and the Use of CVII in the NAT Method in 2000 Units of Noot         Noot           1D Marker         Number of Donations         Positive Findings, No.         P value         OR *         95%C1         Sensitivity         PPV           HIW-RAT         0.0580         6.01         0.738-277.6         0.08571         0.006           No         1000         6         6.3168         1         0.340-157.9         0.375         0.001           No         1000         4         4         1         0.340-157.9         0.375         0.002		17776-1	9623	0.000	10.01	6.52,05.60	0.0158	0.000
Yes         2072         22           "Addressiation: OR, odd rates         "Addressiation: OR, odd rates		258540	177	1011070707			the fire	
Bable 4. The Prevalences of HIW and HCV and the Use of C/IE in the NAT Method in 2000 Units of Blood           ID Marker         Number of Donations         Positive Findings, No.         P value         OR *         93% CI         Sensitivity         PTV           HIV-NAT         0.000         0         0.058/2         6.01         0.21#-277.6         0.006271         0.006           No         1000         0								
ID.Marker         Number of Donations         Positive Findings, No.         P value         OR *         95% CI         Sensitivity         PPV           HDV-NAT         0.0580         6.01         0.228-277.6         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.066         0.001         0.066         0.001	Abbreviation: OF	t, oddt nariot						
No 1000 0 Yes 1000 6 HCV-NAT 0,368 3 0,340-157,9 0,75 0,003 No 1000 0 Yes 1000 4	1D Marker	Number of Donations	POSITIVE EIDENIGN, NO.	1. control				
No         1000         0           Yes         1000         6           HCV-NAT         0.368         0.340-157.9         0.35         0.003           No         1000         0         345         0.340-157.9         0.35         0.003	STA BE AND IN THE						SCHERUNARY.	1110
HCV-NAT 0.368 3 0.340-157.9 0.75 0.003 No 1000 0 395 1000 4		Number of Donations	Positive Hindings, No.			0.738-277.6	0.00571	0.006
No 1000 0 395 1000 4	HIN-NAT No						0.0#371	
No 1000 0 Vis 1000 4	HUV-NAT No Yes	1000	D				0.09571	
	HIIV-NAT No Yes HCV-NAT	1000	D	0.0583	6.01	0.340-157.9	0.75	0.001
	HIIV-NAT No Yes HCV-NAT No	1000	0 8 0	0.0583	6.01	0.340-157.9	0.75	0.001

